WO2000062801A3 - Nouvelles compositions - Google Patents

Nouvelles compositions Download PDF

Info

Publication number
WO2000062801A3
WO2000062801A3 PCT/EP2000/003514 EP0003514W WO0062801A3 WO 2000062801 A3 WO2000062801 A3 WO 2000062801A3 EP 0003514 W EP0003514 W EP 0003514W WO 0062801 A3 WO0062801 A3 WO 0062801A3
Authority
WO
WIPO (PCT)
Prior art keywords
streptococcus pneumoniae
rsv
respiratory syncytial
syncytial virus
vaccine against
Prior art date
Application number
PCT/EP2000/003514
Other languages
English (en)
Other versions
WO2000062801A2 (fr
Inventor
Marguerite Deschamps
Craig Antony Joseph Laferriere
Original Assignee
Smithkline Beecham Biolog
Marguerite Deschamps
Craig Antony Joseph Laferriere
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES00940231T priority Critical patent/ES2304960T3/es
Priority to KR1020017013365A priority patent/KR100632835B1/ko
Priority to BR0010682-8A priority patent/BR0010682A/pt
Priority to DE60038877T priority patent/DE60038877D1/de
Application filed by Smithkline Beecham Biolog, Marguerite Deschamps, Craig Antony Joseph Laferriere filed Critical Smithkline Beecham Biolog
Priority to PL00351894A priority patent/PL351894A1/xx
Priority to IL14598100A priority patent/IL145981A0/xx
Priority to EP00940231A priority patent/EP1171159B1/fr
Priority to NZ514961A priority patent/NZ514961A/en
Priority to AU55233/00A priority patent/AU754101B2/en
Priority to JP2000611937A priority patent/JP2002542204A/ja
Priority to CA002365579A priority patent/CA2365579A1/fr
Publication of WO2000062801A2 publication Critical patent/WO2000062801A2/fr
Publication of WO2000062801A3 publication Critical patent/WO2000062801A3/fr
Priority to NO20015074A priority patent/NO20015074L/no
Priority to HK02104796.6A priority patent/HK1045100A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une composition vaccinale comprenant : (a) au moins un polysaccharide de Streptococcus pneumoniae, soit conjugué à une protéine ou un peptide, soit non conjugué, et (b) un antigène du virus respiratoire syncytial, conjointement avec un adjuvant, lequel est un stimulateur préférentiel de la réponse immune de type Th1. Les vaccins combinés de l'invention sont notamment utiles pour les enfants et les personnes âgées.
PCT/EP2000/003514 1999-04-20 2000-04-17 Nouvelles compositions WO2000062801A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IL14598100A IL145981A0 (en) 1999-04-20 2000-04-17 Vaccine compositions comprising a polysacharide of streptococcus
BR0010682-8A BR0010682A (pt) 1999-04-20 2000-04-17 Novas composições
DE60038877T DE60038877D1 (de) 1999-04-20 2000-04-17 Kombinationsimpfstoff gegen streptokokkus pneumoniae und respiratory syncytial virus (rsv)
NZ514961A NZ514961A (en) 1999-04-20 2000-04-17 Combination vaccines for protection against Streptococcus pneumoniae and RSV infection in children and the elderly
PL00351894A PL351894A1 (en) 1999-04-20 2000-04-17 Novel compositions
KR1020017013365A KR100632835B1 (ko) 1999-04-20 2000-04-17 조성물
EP00940231A EP1171159B1 (fr) 1999-04-20 2000-04-17 Vaccin combine contre le streptococcus pneumoniae et le virus syncytial respiratoire (rsv)
ES00940231T ES2304960T3 (es) 1999-04-20 2000-04-17 Vacuna combinada contra streptococcus pneumoniae y virus sincicial respiratorio (rsv).
AU55233/00A AU754101B2 (en) 1999-04-20 2000-04-17 Novel compositions
JP2000611937A JP2002542204A (ja) 1999-04-20 2000-04-17 ストレプトコッカス・ニューモニエ及び呼吸性シンシチウムウィルス（ｒｓｖ）に対する複合ワクチン
CA002365579A CA2365579A1 (fr) 1999-04-20 2000-04-17 Nouvelles compositions
NO20015074A NO20015074L (no) 1999-04-20 2001-10-18 Nye sammensetninger
HK02104796.6A HK1045100A1 (zh) 1999-04-20 2002-06-27 抗肺炎鏈球菌和呼吸合胞體病毒(rsv)的結合疫苗

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9909077.1 1999-04-20
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09959167 A-371-Of-International 2002-02-19
US10/867,880 Continuation US20040228879A1 (en) 1999-04-20 2004-06-15 Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (RSV)

Publications (2)

Publication Number Publication Date
WO2000062801A2 WO2000062801A2 (fr) 2000-10-26
WO2000062801A3 true WO2000062801A3 (fr) 2001-01-11

Family

ID=10851924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003514 WO2000062801A2 (fr) 1999-04-20 2000-04-17 Nouvelles compositions

Country Status (26)

Country Link
US (1) US20040228879A1 (fr)
EP (2) EP1171159B1 (fr)
JP (1) JP2002542204A (fr)
KR (1) KR100632835B1 (fr)
CN (1) CN1192797C (fr)
AR (1) AR023535A1 (fr)
AT (1) ATE395079T1 (fr)
AU (1) AU754101B2 (fr)
BR (1) BR0010682A (fr)
CA (1) CA2365579A1 (fr)
CO (1) CO5300414A1 (fr)
CZ (1) CZ20013773A3 (fr)
DE (1) DE60038877D1 (fr)
ES (1) ES2304960T3 (fr)
GB (1) GB9909077D0 (fr)
HK (1) HK1045100A1 (fr)
HU (1) HUP0201905A3 (fr)
IL (1) IL145981A0 (fr)
MY (1) MY125000A (fr)
NO (1) NO20015074L (fr)
NZ (1) NZ514961A (fr)
PL (1) PL351894A1 (fr)
TR (1) TR200103012T2 (fr)
TW (1) TWI234463B (fr)
WO (1) WO2000062801A2 (fr)
ZA (1) ZA200108620B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7815920B2 (en) 1998-09-21 2010-10-19 Allergy Therapeutics (UK) Ltd Method of preparing an antigen-containing formulation
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
EP1880735A3 (fr) * 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccin
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
FR2828406B1 (fr) * 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
ME01334B (me) 2005-04-08 2013-12-20 Wyeth Llc Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2612680B1 (fr) * 2008-04-16 2018-05-23 GlaxoSmithKline Biologicals SA Vaccin
EP3020412B1 (fr) * 2009-06-16 2017-10-11 The Regents of the University of Michigan Vaccins en nanoémulsion
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
CN101703769B (zh) * 2009-11-13 2013-05-08 广东永顺生物制药股份有限公司 一种新型猪链球菌病四价灭活疫苗
KR101609032B1 (ko) * 2010-06-04 2016-04-04 와이어쓰 엘엘씨 스트렙토코커스 뉴모니아 백신 제제
BR112017011234A2 (pt) 2014-12-10 2018-03-27 Genentech Inc anticorpos contra receptor da barreira hematoencefálica e métodos de uso
US10159728B2 (en) 2015-09-10 2018-12-25 Inventprise, Llc Multivalent VLP conjugates
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2023218322A1 (fr) 2022-05-11 2023-11-16 Pfizer Inc. Procédé de production de formulations de vaccin avec des conservateurs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032963A1 (fr) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Declenchement et renforcement de la reaction immunitaire aux polysaccharides a l'aide de lipoproteines bacteriennes
WO1996033739A1 (fr) * 1995-04-25 1996-10-31 Smithkline Beecham Biologicals S.A. Vaccins contenant une saponine ainsi qu'un sterol
WO1998018819A1 (fr) * 1996-10-29 1998-05-07 Smithkline Beecham Biologicals S.A. Purification d'antigenes du virus respiratoire syncytial
US5750110A (en) * 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
US5837250A (en) * 1994-06-16 1998-11-17 Connaught Laboratories Limited Adjuvant compositions
WO1998051339A1 (fr) * 1997-05-14 1998-11-19 Pasteur Merieux Serums & Vaccins Composition vaccinale multivalente a porteur mixte

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU617739B2 (en) 1987-12-23 1991-12-05 Pharmacia & Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
DK0705109T4 (da) * 1993-05-25 2004-05-10 Wyeth Corp Adjuvanser til vacciner mod respiratorisk syncytialvirus
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (fr) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Oligonucleotides immunomodulateurs
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
EP0866871A1 (fr) * 1995-12-06 1998-09-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Compositions et procede servant a stimuler la liberation d'anticorps par les lymphocytes b
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750110A (en) * 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
US5837250A (en) * 1994-06-16 1998-11-17 Connaught Laboratories Limited Adjuvant compositions
WO1996032963A1 (fr) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Declenchement et renforcement de la reaction immunitaire aux polysaccharides a l'aide de lipoproteines bacteriennes
WO1996033739A1 (fr) * 1995-04-25 1996-10-31 Smithkline Beecham Biologicals S.A. Vaccins contenant une saponine ainsi qu'un sterol
WO1998018819A1 (fr) * 1996-10-29 1998-05-07 Smithkline Beecham Biologicals S.A. Purification d'antigenes du virus respiratoire syncytial
WO1998051339A1 (fr) * 1997-05-14 1998-11-19 Pasteur Merieux Serums & Vaccins Composition vaccinale multivalente a porteur mixte

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FLETCHER T J ET AL: "Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease.", BMJ, vol. 314, no. 7095, 1997, pages 1663 - 1665, XP000952814 *
GIEBINK G SCOTT: "Immunology: Promise of new vaccines.", PEDIATRIC INFECTIOUS DISEASE JOURNAL, vol. 13, no. 11, 1994, pages 1064 - 1068, XP000952829, ISSN: 0891-3668 *
LEE CHI-JEN ET AL: "Immunologic epitope, gene, and immunity involved in pneumococcal glycoconjugate.", CRITICAL REVIEWS IN MICROBIOLOGY, vol. 23, no. 2, 1997, pages 121 - 142, XP000946772, ISSN: 1040-841X *
SCHNEERSON R ET AL: "EVALUATION OF MONOPHOSPHORYL LIPID A MPL AS AN ADJUVANT ENHANCEMENT OF THE SERUM ANTIBODY RESPONSE IN MICE TO POLYSACCHARIDE-PROTEIN CONJUGATES BY CONCURRENT INJECTION WITH MPL", JOURNAL OF IMMUNOLOGY, vol. 147, no. 7, 1991, pages 2136 - 2140, XP002149961, ISSN: 0022-1767 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7815920B2 (en) 1998-09-21 2010-10-19 Allergy Therapeutics (UK) Ltd Method of preparing an antigen-containing formulation
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Also Published As

Publication number Publication date
DE60038877D1 (de) 2008-06-26
ZA200108620B (en) 2002-09-13
KR100632835B1 (ko) 2006-10-16
CN1192797C (zh) 2005-03-16
MY125000A (en) 2006-07-31
KR20010110784A (ko) 2001-12-13
EP1927366A1 (fr) 2008-06-04
HK1045100A1 (zh) 2002-11-15
CZ20013773A3 (cs) 2002-05-15
ES2304960T3 (es) 2008-11-01
NO20015074D0 (no) 2001-10-18
EP1171159B1 (fr) 2008-05-14
CO5300414A1 (es) 2003-07-31
US20040228879A1 (en) 2004-11-18
HUP0201905A2 (en) 2002-09-28
HUP0201905A3 (en) 2003-12-29
BR0010682A (pt) 2002-02-05
EP1171159A2 (fr) 2002-01-16
ATE395079T1 (de) 2008-05-15
AR023535A1 (es) 2002-09-04
CA2365579A1 (fr) 2000-10-26
PL351894A1 (en) 2003-06-30
GB9909077D0 (en) 1999-06-16
JP2002542204A (ja) 2002-12-10
IL145981A0 (en) 2002-07-25
CN1355710A (zh) 2002-06-26
WO2000062801A2 (fr) 2000-10-26
NO20015074L (no) 2001-11-15
TWI234463B (en) 2005-06-21
AU5523300A (en) 2000-11-02
TR200103012T2 (tr) 2002-06-21
AU754101B2 (en) 2002-11-07
NZ514961A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
WO2000062801A3 (fr) Nouvelles compositions
WO2000056359A3 (fr) Vaccin
WO2000062800A3 (fr) Vaccins
WO2002013857A3 (fr) Vaccin comprenant au moins un antigene et un peptide antimicrobien a base de cathelicidine ou un derive de ce peptide
WO2000076540A3 (fr) Proteines et vaccins de streptococcus pneumoniae
WO2004041157A3 (fr) Vaccin contre les streptocoques du groupe b
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
EP2275122A3 (fr) Vaccins contre le streptococcus pneumoniae à base de protéine
WO2002028422A3 (fr) Vaccin
CA2201598A1 (fr) Compositions vaccinales
WO2002022168A3 (fr) Vaccin
WO2006085983A3 (fr) Adjuvants viraux
EP0955059A3 (fr) Vaccins contenant une saponine ainsi qu'un sterol
WO2003084467A3 (fr) Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene
WO2005084306A3 (fr) Compositions immunogenes pour chlamydia pneunomiae
WO2002028426A8 (fr) Vaccin
WO2003051392A3 (fr) Vaccin
WO2001058485A3 (fr) Anticorps monoclonaux a vocation prophylactique et therapeutique
WO2001081380A3 (fr) Proteine pneumococcique immunogenique et ses compositions de vaccins
WO2000062802A3 (fr) Vaccin
WO2002070004A3 (fr) Immunogenes et vaccins ainsi que leur preparation et leur utilisation
WO2004092207A3 (fr) Peptides du virus respiratoire syncytial (rsv)
CA2273922A1 (fr) Nouvelles compositions a base de saponine et leurs utilisations
EP1905449A3 (fr) Composition adjuvante continant une saponine et un oligonucleotide immunostimulateur
WO2002004497A3 (fr) Peptides a antigenes multiples assurant l'immunite contre streptococcus pneumoniae

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00809053.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1442/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000940231

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2365579

Country of ref document: CA

Ref document number: 2365579

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 55233/00

Country of ref document: AU

Ref document number: 2001/03012

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 611937

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 514961

Country of ref document: NZ

Ref document number: 1020017013365

Country of ref document: KR

Ref document number: PA/a/2001/010653

Country of ref document: MX

Ref document number: PV2001-3773

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017013365

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000940231

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09959167

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-3773

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 55233/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020017013365

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-3773

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2000940231

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)